Last reviewed · How we verify
Insulin/Empaglifozin
This combination uses insulin to lower blood glucose while empaglifozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects.
This combination uses insulin to lower blood glucose while empaglifozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin/Empaglifozin |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Insulin + SGLT2 inhibitor combination |
| Target | Insulin receptor; SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin acts as an exogenous hormone replacement to facilitate glucose uptake into cells and suppress hepatic glucose production. Empaglifozin, an SGLT2 inhibitor, blocks reabsorption of filtered glucose in the proximal tubule, allowing excess glucose to be excreted in urine. Together, they provide dual mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Genital mycotic infections
- Urinary tract infections
- Volume depletion
- Diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin/Empaglifozin CI brief — competitive landscape report
- Insulin/Empaglifozin updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI